Pulmonary Medicine

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Mindful Breathing Awareness Through Pursed-Lip Breathing Training

   Rochester, Minn.

   To establish the feasibility of a tool that monitors and motivates people with COPD to complete training in mindful pursed-lip breathing to enhance pulmonary rehabilitation at home.

2. Timing and Intensity of the Exposures and Attributable Burden of Acute Lung Injury

   Rochester, Minn.

   The purpose of the study is to identify the patients at high risk of developing Acute Lung Injury (ALI) at the time of hospital admission, and before intensive care unit admission.

   Aim 1- To validate the prediction model (Lung Injury Prediction Score) in a population based sample of hospitalized patients.

   Aim 2- To determine the significance of health-care related ALI risk modifiers in a population based sample.

   Aim 3- To compare the short and long term outcomes between patients at high risk who do, and do not develop ALI.

3. A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

   Scottsdale/Phoenix, Ariz.

   This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib [TARCEVA®]), gemcitabine or vinorelbine (NAVELBINE®).

4. A Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in Idiopathic Pulmonary Fibrosis (IPF)

   Rochester, Minn.

   The purpose of this study is to evaluate Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer, for the treatment of persistent cough in patients with idiopathic pulmonary fibrosis (IPF).

5. Influence of Immunosuppresion on Lung Iron Content in Pneumonia

   Scottsdale/Phoenix, Ariz.

   The purpose of the study is to see whether lung concentrations of iron and a protein that binds iron are influenced by the presence of pneumonia. Increased amounts of iron in the lungs may promote the growth or microorganisms and may influence the severity of lung injury caused by an infection. We are comparing the amount of iron that accumulates in the lungs in response to pneumonia in different types of patients.

6. Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

   Jacksonville, Fla., Rochester, Minn.

   This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 314 patients at approximately 120 clinical trial centers. The treatment phase of the study will last approximately 16 weeks. Patients who complete all required assessments will also be eligible to enter an open-label, extension study (RIN-PH-202).

7. Impulse Oscillometry in Idiopathic Subglottic StenosisCap

   Rochester, Minn.

   The purpose of this study is to describe impulse oscillometry (IOS) in patients with symptomatic idiopathic subglottic stenosis (iSGS). The study will also compare IOS findings in patients with iSGS with IOS findings in patients with small airways obstruction and in healthy controls.

    

8. Study to Determine Eligibility for Lung Cancer Screening in Patients with Acute or Prior Cerebrovascular Accident (CVA)

   Jacksonville, Fla.

   The purpose of this study is to describe in detail the smoking history in a population of acute or prior cerebrovasculqar accident (CVA) patients and identify those who qualify for lung cancer screening by criteria outlined by three separate organizations.

9. Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

   Rochester, Minn.

   The purpose of this clinical trial is to determine if low dose naltrexone is effective in improving health-related quality of life (HRQoL) among patients with vasculitis. Although it is a pilot study, a placebo-controlled component is used because of the prominent placebo group effect seen in studies with self-reported subjective outcomes.

   Naltrexone is an FDA approved drug (for alcoholism) that has found widespread use "off-label" to treat pain and improve quality of life at much lower doses than are used for the approved indication. There are a few scientific studies in three conditions (fibromyalgia, Crohn's disease, and multiple sclerosis) that suggest that this drug has benefit and is safe. However, considering the extent of use in other conditions, and uncertainty about the mechanism of action study is needed in a diverse set of diseases, including vasculitis.

10. A Study to Evaluate Whether or Not Selexipag is Effective and Safe in Patients with Chronic Thromboembolic Pulmonary Hypertension when the Disease is Inoperable or Persistent/Recurrent After Surgery

    Jacksonville, Fla.

    The purpose of this study is to assess the effectiveness and safety of selexipag in subjects with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH).